Clinical Trials Logo

Acute Limb Ischemia clinical trials

View clinical trials related to Acute Limb Ischemia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06446024 Recruiting - Acute Limb Ischemia Clinical Trials

Post Market Surveillance to Evaluate the Efficacy and Safety of the INDIGO Aspiration System in Japan

JapanIndigoPMS
Start date: December 7, 2023
Phase:
Study type: Observational [Patient Registry]

This study aims to confirm the safety and effectiveness of the INDIGO Aspiration System in patients requiring immediate treatment for acute lower extremity artery occlusion, acute superior mesenteric artery occlusion, or severe acute deep vein thrombosis. Primary objective of the study is to collect predetermined data on use, safety and effectiveness, including clinical and technical performance of the INDIGO System in Japan.

NCT ID: NCT06222658 Recruiting - Acute Limb Ischemia Clinical Trials

The Role of Pharmaco-mechanical Thrombectomy in Management of Acute Lower Extremity Arterial Ischemia

Start date: January 20, 2024
Phase: N/A
Study type: Interventional

The goal of our protocol is to re-establish patency in ALLI, by combining both balloon maceration of a thrombus and angiojet PMT thus decreasing complications associated with prolonged periods of thrombolytic exposure while avoid open surgical risk .

NCT ID: NCT05868161 Recruiting - Clinical trials for Peripheral Arterial Disease

Pounce™ Thrombectomy System Retrospective Registry

PROWL
Start date: April 18, 2023
Phase:
Study type: Observational

The PROWL registry is an open-label retrospective, multi-center, US study of the Surmodics™ Pounce™ Thrombectomy System for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature.

NCT ID: NCT05372718 Recruiting - Acute Limb Ischemia Clinical Trials

Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial

FORAT
Start date: December 26, 2022
Phase: Phase 3
Study type: Interventional

Objective: to evaluate the efficacy and safety of intra-arterial intrathrombus administration of the recombinant non-immunogenic staphylokinase (Fortelyzin®) in patients with acute limb ischemia (ALI) vs surgery.